Janux Therapeutics, Inc.
JANX
$28.80
$1.937.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.99% | 54.12% | 94.86% | -19.67% | -6.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.99% | 54.12% | 94.86% | -19.67% | -6.14% |
| Cost of Revenue | 24.52% | 2.94% | -11.44% | -10.14% | 2.77% |
| Gross Profit | -23.40% | 5.79% | 27.25% | 8.41% | -4.48% |
| SG&A Expenses | 57.03% | 53.92% | 11.30% | 13.63% | 17.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.00% | 18.47% | -4.72% | -3.32% | 7.08% |
| Operating Income | -35.45% | -14.45% | 14.72% | 1.32% | -8.78% |
| Income Before Tax | -18.36% | 3.30% | 34.97% | 17.16% | 7.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.36% | 3.30% | 34.97% | 17.16% | 7.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.36% | 3.30% | 34.97% | 17.16% | 7.56% |
| EBIT | -35.45% | -14.45% | 14.72% | 1.32% | -8.78% |
| EBITDA | -36.27% | -14.47% | 15.68% | 2.47% | -7.21% |
| EPS Basic | 4.61% | 20.33% | 43.67% | 24.13% | 11.77% |
| Normalized Basic EPS | 4.62% | 20.34% | 43.67% | 24.14% | 11.77% |
| EPS Diluted | 4.61% | 20.33% | 43.67% | 24.13% | 11.77% |
| Normalized Diluted EPS | 4.62% | 20.34% | 43.67% | 24.14% | 11.77% |
| Average Basic Shares Outstanding | 22.14% | 19.85% | 17.50% | 10.19% | 6.10% |
| Average Diluted Shares Outstanding | 22.14% | 19.85% | 17.50% | 10.19% | 6.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
